Thalidomide
Therapeutic Group
ImmunosuppressantsIndication Dosage
First-line Treatment For Untreated Multiple Myeloma, In Patients Aged 65 Years And Over, Or For Those Not Eligible For High-dose Chemotherapy Due To Significant Co-morbidity Such As Cardiac Risk Factors (in Combination With Melphalan And Prednisolone):
- Adult 18-75 Years: 200 Mg Once Daily At Bedtime For a 6-week Cycle For A Maximum Of 12 Cycles
- Adult 76 Years And Above: 100 Mg Once Daily At Bedtime for a 6-week Cycle For A Maximum Of 12 Cycles
Content
- Cap 50mg /100mg: Thalidomide 50mg /100mg.
Pregnancy
Positive Evidence Of Risk: Avoid
Stability
- Immunomodulator and Anti-inflammatory
Contra Indications
- Patients With Pre-existing Peripheral Neuropathy Should Not Be Treated With Thalidomide Unless The Potential Clinical Benefits Outweigh The Risk
Precautions
- Patients With Pre-existing Peripheral Neuropathy Should Not Be Treated With Thalidomide Unless The Potential Clinical Benefits Outweigh The Risk
Lactation
- Contraindicated. Discontinue Breast-feeding
Side Effects
- Anaemia
- Asthenia
- Bradycardia
- Cardiac Failure
- Confusion
- Constipation
- Deep Veinthrombosis
- Depression
- Dizziness
- Drowsiness
- Dysaesthesia
- Dyspepsia
- Dyspnea
- Interstitial Lung Disease
- Leucopenia
- Lymphopenia
- Neutropenia
- Paraesthesia
- Peripheral Neuropathy
- Peripheral Oedema
- Pneumonia
- Pulmonary Embolism
- Pyrexia
- Skin Reactions
- Stevens-johnson Syndrome
- Syncope
- Thrombocytopenia
- Tremor
- Vomiting
- Atrial Fibrillation
- Atrioventricular Block
- Cerebrovascular Events
- Convulsions
- Gi Haemorrhage
- Gi Perforation
- Hepatic Disorders
- Hypothyroidism
- Intestinal Obstruction
- Myocardial Infarction
- Renal Failure
- Second Primary Malignancy
- Toxic Epidermal Necrolysis